The Final Phase of Invitae’s Corporate Dissolution
The corporate liquidation process for genetic testing firm Invitae is nearing its formal conclusion. This stage represents the administrative endgame for investors, marking the terminal point of a prolonged restructuring effort. The company’s core diagnostic operations were fully transferred to a larger laboratory conglomerate two years ago, in 2024, leaving only the corporate shell to…

